Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial

Br J Psychiatry. 2009 Jun;194(6):541-6. doi: 10.1192/bjp.bp.108.055319.

Abstract

Background: Naltrexone has considerable potential in helping to prevent relapse in heroin dependency. A longer-lasting formulation for naltrexone treatment is desirable to further reduce non-adherence and relapse during treatment of opiate dependence.

Aims: To evaluate the safety and effectiveness of a 6-month naltrexone implant in reducing opioid use after in-patient treatment.

Method: A group of 56 abstinence-oriented patients who completed in-patient treatment for opioid dependence were randomly and openly assigned to receive either a 6-month naltrexone implant or their usual aftercare. Drug use and other outcomes were assessed at 6-month follow-up.

Results: Patients receiving naltrexone had on average 45 days less heroin use and 60 days less opioid use than controls in the 180-day period (both P<0.05). Blood tests showed naltrexone levels above 1 ng/ml for the duration of 6 months. Two patients died, neither of whom had received an implant.

Conclusions: Naltrexone implant treatment safely and significantly reduces opioid use in a motivated population of patients.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Drug Implants
  • Female
  • Follow-Up Studies
  • Heroin Dependence / drug therapy*
  • Heroin Dependence / rehabilitation
  • Humans
  • Male
  • Middle Aged
  • Motivation
  • Naltrexone / blood
  • Naltrexone / therapeutic use*
  • Narcotic Antagonists / blood
  • Narcotic Antagonists / therapeutic use*
  • Norway
  • Secondary Prevention
  • Treatment Outcome
  • Young Adult

Substances

  • Drug Implants
  • Narcotic Antagonists
  • Naltrexone